Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease



Rating:

Share or cite this content

Citations should be made in the following way:
L. Kaiser (Munich, Germany), S. Hardy (Munich, Germany), M. Frankenberger (Munich, Germany), K. Milger (Munich, Germany), S. Meiners (Munich, Germany). Immunoproteasome function as a potential biomarker for asthma severity and response to therapy. 869

Member's Comments

No comment yet.

Related content which might interest you: Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020 Year: 2021 Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD Source: International Congress 2017 – COPD management Year: 2017 The role of biomarkers in the management of severe asthma Source: International Congress 2019 – Severe asthma guidelines: update 2019 Year: 2019 Distribution of therapeutic response in asthma control Source: Eur Respir J 2003; 22: 568 Year: 2003 Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 The role of airways 17ß-estradiol as a biomarker of severity in post-menopausal asthma Source: Virtual Congress 2020 – Respiratory homeostasis and structural changes in disease Year: 2020 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 The role of Hs-CRP in evaluating asthma severity and asthma control Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Is a degree of asthma therapy related to pulmonary function impairment? Source: Eur Respir J 2001; 18: Suppl. 33, 41s Year: 2001 Discrepancy of non-invasive inflammatory markers and lung function tests to current level of clinical control in childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009 The eNose as a predictor of disease severity and treatment response Source: International Congress 2015 – Individualised risk reduction strategies for patients with COPD Year: 2015 Effect of GERD on clinical severity and functional characteristics of lung function in asthma Source: Annual Congress 2011 - Clinical parameters in airway diseases Year: 2011 Can YKL-40 be used as a biomarker and therapeutic target for adult asthma? Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017 Year: 2018 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Systemic inflammatory response in relation to disease severity and nutritional depletion in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 31s Year: 2004 TH2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001